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1. INTRODUCTION 
1.1 ORAL CONTROLLED DRUG DELIVERY SYSTEM  
Oral drug delivery is the most widely utilized route of administration among 
all the routes that have been explored for systemic delivery of drugs via 
pharmaceutical products of different dosage form. Oral route is considered most 
natural, uncomplicated, convenient and safe due to its ease of administration, patient 
acceptance, and cost-effective manufacturing process.1 
Pharmaceutical products designed for oral delivery are mainly immediate 
release type or conventional drug delivery systems, which are designed for 
immediate release of drug for rapid absorption. These immediate release dosage 
forms have some limitations such as.2,3 
1) Drugs with short half-life requires frequent administration, which increases 
chances of missing dose of drug leading to poor patient compliance 
2)  A typical peak-valley plasma concentration-time profile is obtained which 
makes attainment of steady state condition difficult. 
3)  The unavoidable fluctuations in the drug concentration may lead to under 
medication or overmedication as the CSS values fall or rise beyond the 
therapeutic range. 
4)  The fluctuating drug levels may lead to precipitation of adverse effects 
especially of a drug with small therapeutic index, whenever overmedication 
occurs. 
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In order to overcome the drawbacks of conventional drug delivery systems, 
several technical advancements have led to the development of controlled drug 
delivery system that could revolutionize method of medication and provide a 
number of therapeutic benefits.4 
 
Fig.1: A hypothetical plasma concentration-time profile from conventional 
multiple dosing and single doses of sustained and controlled delivery formulations.  
Controlled Drug Delivery Systems: 
Controlled drug delivery systems have been developed which are capable of 
controlling the rate of drug delivery, sustaining the duration of therapeutic activity 
and/or targeting the delivery of drug to a tissue.5 
Controlled drug delivery or modified drug delivery systems are conveniently 
divided into four categories. 
1) Delayed release 
2) Sustained release 
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3) Site-specific targeting 
4) Receptor targeting 
More precisely, controlled delivery can be defined as6  
1)  Sustained drug action at a predetermined rate by maintaining a relatively 
constant, effective drug level in the body with concomitant minimization of 
undesirable side effects. 
2)  Localized drug action by spatial placement of a controlled release system 
adjacent to or in the diseased tissue. 
3)  Targeted drug action by using carriers or chemical derivatives to deliver drug to 
a particular target cell type. 
4)  Provide a physiologically / therapeutically based drug release system. In other 
words, the amount and the rate of drug release are determined by the 
physiological/ therapeutic needs of the body. 
A controlled drug delivery system is usually designed to deliver the drug at 
particular rate. Safe and effective blood levels are maintained for a period as long as 
the system continues to deliver the drug. Controlled drug delivery usually results in 
substantially constant blood levels of the active ingredient as compared to the 
uncontrolled fluctuations observed when multiple doses of quick releasing 
conventional dosage forms are administered to a patient. 
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Advantages of Controlled Drug Delivery System: 
1. Avoid patient compliance problems. 
2. Employ less total drug 
a) Minimize or eliminate local side effects 
b) Minimize or eliminate systemic side effects 
c) Obtain less potentiation or reduction in drug activity with chronic use. 
d) Minimize drug accumulation with chronic dosing. 
3. Improve efficiency in treatment 
a) Cures or controls condition more promptly. 
b) Improves control of condition i.e., reduced fluctuation in drug level. 
c) Improves bioavailability of some drugs. 
d) Make use of special effects, E.g. Sustained-release aspirin for morning 
relief of arthritis by dosing before bed time. 
4. Economy i.e. reduction in health care costs. The average cost of treatment over an 
extended time period may be less, with less frequency of dosing, enhanced 
therapeutic benefits and reduced side effects. The time required for health care 
personnel to dispense and administer the drug and monitor patient is also reduced. 
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Disadvantages:7 
1) Decreased systemic availability in comparison to immediate release 
conventional dosage forms, which may be due to incomplete release, increased 
first-pass metabolism, increased instability, insufficient residence time for 
complete release, site specific absorption, pH dependent stability etc. 
2) Poor in vitro – in vivo correlation. 
3) Possibility of dose dumping due to food, physiologic or formulation variables or 
chewing or grinding of oral formulations by the patient and thus, increased risk 
of toxicity. 
4) Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity 
reactions. 
5) Reduced potential for dosage adjustment of drugs normally administered in 
varying strengths. 
Oral Controlled Drug Delivery Systems:8 
Oral controlled release drug delivery is a drug delivery system that provides 
the continuous oral delivery of drugs at predictable and reproducible kinetics for a 
predetermined period throughout the course of GI transit and also the system that 
target the delivery of a drug to a specific region within the GI tract for either a local 
or systemic action. 
All the pharmaceutical products formulated for systemic delivery via the oral 
route of administration, irrespective of the mode of delivery (immediate, sustained 
or controlled release) and the design of dosage form (either solid, dispersion or 
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liquid), must be developed within the intrinsic characteristics of GI physiology. 
Therefore the scientific framework required for the successful development of an 
oral drug delivery systems consists of basic understanding of 
(i) Physicochemical, pharmacokinetic and pharmacodynamic characteristics of 
the drug;  
(ii) The anatomic and physiologic characteristics of the gastrointestinal tract and 
(iii) Physicochemical characteristics and the drug delivery mode of the dosage form 
to be designed. 
The main areas of potential challenge in the development of oral controlled 
drug delivery systems are 9 
1) Development of a drug delivery system: To develop a viable oral controlled 
release drug delivery system capable of delivering a drug at a therapeutically 
effective rate to a desirable site for a duration required for optimal treatment. 
2) Modulation of gastrointestinal transit time: To modulate the GI transit time 
so that the drug delivery system developed can be transported to a target site 
or to the vicinity of an absorption site and reside there for a prolonged  
period of time to maximize the delivery of a drug dose. 
3) Minimization of hepatic first pass elimination: If the drug to be delivered is 
subjected to extensive hepatic first-pass elimination, preventive measures 
should be devised to either bypass or minimize the extent of hepatic 
metabolic effect. 
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Conventional oral controlled dosage forms suffer from mainly two 
adversities.10 The short gastric retention time (GRT) and unpredictable gastric 
emptying time (GET). A relatively brief GI transit time of most drug products 
impedes the formulation of single daily dosage forms. These problems can be 
overwhelmed by altering the gastric emptying. Therefore it is desirable, to formulate 
a controlled release dosage form that gives an extended GI residence time. 
Extended release dosage form with prolonged residence time in stomach are 
highly desirable for drugs.11,12  
i) That are locally active in stomach, 
ii) That have an absorption window in the stomach or in the upper small intestine, 
iii) That are unstable in the intestinal or colonic environment, 
iv) Have low solubility at high pH values. 
1.2   Gastro retentive Dosage Form (GRDF): 
It is evident from the recent scientific and patient literature that an increased 
interest in novel dosage forms that are retained in stomach for a prolonged and 
predictable period of time exists today in academic and industrial research groups. 
One of the most feasible approaches for achieving a prolonged and predictable drug 
delivery in the GI tract is to control the gastric residence time (GRT), i.e. gastro 
retentive dosage form (GRDF or GRDS).13 
GRDFs extend significantly the period of time over which the drugs may be 
released. They not only prolong dosing intervals, but also increase patient 
compliance beyond the level of existing controlled release dosage form.14 
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Dosage form with prolonged GRT, i.e. gastro retentive dosage forms 
(GRDF), will bring about new and important therapeutic options such as15  
1) This application is especially effective in sparingly soluble and insoluble drugs. 
It is known that, as the solubility of a drug decreases, the time available for drug 
dissolution becomes less adequate and thus the transit time becomes a significant 
factor affecting drug absorption. To override this problem, erodible, gastro 
retentive dosage forms have been developed that provide continuous, controlled 
administration of sparingly soluble drugs at the absorption site. 
2) GRDFs greatly improve the pharmacotherapy of the stomach through local drug 
release, leading to high drug concentration at the gastric mucosa. (For e.g. 
Eradicating Helicobacter pylori from the submucosal tissue of stomach) making 
it possible to treat stomach and duodenal ulcers, gastritis and oesophagitis, 
reduce the risk of gastric carcinoma and administer non-systemic controlled 
release antacid formulations (calcium carbonate). 
3) GRDFs can be used as carriers for drugs with so-called absorption windows. 
These substances for e.g. antiviral, antifungal and antibiotic agents 
(sulphonamides, quinolones, penicillins, cephalosporins, aminoglycosides, 
tetracyclines etc.), are taken up only from very specific sites of the GI mucosa. 
1.3   BIOLOGICAL ASPECTS OF GRDFs: 
Role of GI tract: Stomach16,17 
The stomach is J-shaped organ located in the upper left hand portion of the 
abdomen, just below the diaphragm. It occupies a portion of the epigastric and left 
hydrochondriac region. The main function of the stomach is to store the food 
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temporarily, grind it and then release it slowly into the duodenum. Due to its small 
surface area very little absorption takes place from the stomach. It provides barrier 
to the delivery of drugs to small intestine. 
 
Fig.2: Anatomy of Stomach 
The stomach is divided into three anatomical regions. I)Fundus ii) Body and 
iii) Pylorus (or antrum). The proximal stomach consisted of fundus and body, which 
serves as a reservoir for ingested materials, whereas the distal region (pylorus) is the 
major site of mixing motions, acting as a pump to propel gastric contents for gastric 
emptying. Gastric emptying occurs both in fasting as well as fed states. 
The GI tract is always in a state of continuous motility. There are two modes 
of motility pattern. The digestive mode and interdigestive mode. In case of fasted 
state an interdigestive series of electrical events occurs in cyclic manner both 
through stomach and small intestine every 2-3 hr. This electrical activity is termed 
as interdigestive myoelectric cycle or migrating myoelectric complex (MMC), 
which is further divided into four phases.18,19 
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Phase I : Period of no contraction. 
Phase II : Period of intermittent contraction. 
Phase III  : Period of regular contractions at the maximal frequency that  
  migrate distally. 
Phase IV  : Period of transition between phase III and phase I. 
Phase III has a housekeeping role and serves to clear all indigestible 
materials from the stomach and small intestine. Consequently, a controlled-release  
gastrointestinal drug delivery system must be capable of resisting the house  keeping 
action of phase III. Studies revealed that in the fed state, the gastric emptying rate is 
slowed since the onset of MMC is delayed. It can be concluded that feeding results 
in a lag time before onset of gastric emptying cycle. 
1.4   APPROACHES TO GASTRIC RETENTION20 
A number of approaches have been used to increase the GRT of a dosage 
form in stomach by employing a variety of concepts. These include– 
a) Floating Systems: 
Floating Drug Delivery Systems (FDDS) 21 have a bulk density lower than 
gastric fluids and thus remain buoyant in the stomach for a prolonged period of time, 
without affecting the gastric emptying rate. While the system is floating on the 
gastric contents, the drug is released slowly at a desired rate from the system. 
After the release of the drug, the residual system is emptied from the 
stomach.  This results in an increase in the GRT and a better control of fluctuations 
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in the plasma drug concentrations. Floating systems can be classified into two 
distinct categories, non-effervescent and effervescent systems. 
 
Fig. 3: Graphic of Buoyant tablet which is less dense than the stomach fluid and 
therefore remains in the fundus. 
b) Bio/Muco-adhesive Systems:22 
Bio/muco-adhesive systems are those which bind to the gastric epithelial cell 
surface or mucin and serve as a potential means of extending the GRT of drug 
delivery system (DDS) in the stomach, by increasing the intimacy and duration of 
contact of drug with the biological membrane. 
The surface epithelial adhesive properties of mucin have been well 
recognized and applied to the development of GRDDS based on bio/muco-adhesive 
polymers. The ability to provide adhesion of a drug (or a delivery system) to the GI 
wall provides a longer residence time in a particular organ site, thereby producing an 
improved effect in terms of local action or systemic effect. 
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Binding of polymers to the mucin/epithelial surface can be divided into three 
broad categories :– 
Hydration-mediated adhesion. 
Bonding-mediated adhesion. 
Receptor-mediated adhesion. 
c) Swelling and Expanding Systems:23 
These are the dosage forms, which after swallowing, swell to an extent that 
prevents their exit from the pylorus. As a result, the dosage form is retained in the 
stomach for a long period of time. These systems may be named as “plug type 
system”, since they exhibit the tendency to remain logged at the pyloric sphincter if 
that exceed a diameter of approximately 12-18 mm in their expanded state. The 
formulation is designed for gastric retention and controlled delivery of the drug into 
the gastric cavity. Such polymeric matrices remain in the gastric cavity for several 
hours even in the fed state.  
A balance between the extent and duration of swelling is maintained by the 
degree of cross-linking between the polymeric chains. A high degree of cross-
linking retards the swelling ability of the system maintaining its physical integrity 
for prolonged period. 
d) High Density Systems:24 
These systems with a density of about 3 gm/cm3 are retained in the rugae of 
the stomach and are capable of withstanding its peristaltic movements. A density of 
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2.6-2.8 g/cm3 acts as a threshold value after which such systems can be retained in 
the lower part of the stomach. High-density formulations include coated pellets. 
Coating is done by heavy inert material such as barium sulphate, zinc oxide, 
titanium dioxide, iron powder etc. They are retained in the antrum of stomach as 
shown in Fig. 4. 
 
Fig. 4: Graphic of heavy tablet which is denser than the stomach fluid and 
therefore sinks to the antrum. 
e) Incorporation of Passage Delaying Food Agents:-25 
Food excipients like fatty acids e.g. salts of myristic acid change and modify 
the pattern of the stomach to a fed state, thereby decreasing gastric emptying rate 
and permitting considerable prolongation of release. The delay in the gastric 
emptying after meals rich in fats is largely caused by saturated fatty acids with chain 
length of C10-C14. 
f) Ion Exchange Resins:26 
A coated ion exchange resin bead formulation has been shown to have 
gastric retentive properties, which was loaded with bicarbonates. Ion exchange 
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resins are loaded with bicarbonate and a negatively charged drug is bound to the 
resin. The resultant beads were then encapsulated in a semi-permeable membrane to 
overcome the rapid loss of carbon dioxide. Upon arrival in the acidic environment of 
the stomach, an exchange of chloride and bicarbonate ions take place. As a result of 
this reaction carbon dioxide was released and trapped in the membrane thereby 
carrying beads towards the top of gastric content and producing a floating layer of 
resin beads in contrast to the uncoated beads, which will sink quickly. 
g) Osmotic Regulated Systems:10 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a bioerodible capsule. In the stomach the capsule 
quickly disintegrates to release the intragastric osmotically controlled drug delivery 
device. The inflatable support inside forms a deformable hollow polymeric bag that 
contains a liquid that gasifies at body temperature to inflate the bag. The osmotic 
controlled drug delivery device consists of two components – drug reservoir 
compartment and osmotically active compartment. 
1.5  TYPES OF FLOATING DRUG DELIVERY SYSTEMS (FDDS)27,28 
Based on the mechanism of buoyancy, two distinctly different technologies 
have been utilized in development of FDDS which are : 
A. Effervescent System, and 
B. Non- Effervescent System. 
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A. EFFERVESCENT SYSTEM:- 
Effervescent systems include use of gas generating agents, carbonates (ex. 
Sodium bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present 
in the formulation to produce carbon dioxide (CO2) gas, thus reducing the density of 
the system and making it float on the gastric fluid. An alternative is the 
incorporation of matrix containing portion of liquid, which produce gas that 
evaporate at body temperature. 
These effervescent systems further classified into two types. 
I. Gas Generating systems 
II. Volatile Liquid/Vacuum Containing Systems. 
I. Gas – Generating Systems: 
1. Intra Gastric Single Layer Floating Tablets or Hydrodynamically Balanced 
Sysem (HBS): 
These are as shown in Fig.5 and formulated by intimately mixing the CO2 
generating agents and the drug with in the matrix tablet. 
These have a bulk density lower than gastric fluids and therefore remain 
floating in the stomach unflattering the gastric emptying rate for a prolonged period. 
The drug is slowly released at a desired rate from the floating system and after the 
complete release the residual system is expelled from the stomach. This leads to an 
increase in the GRT and a better control over fluctuations in plasma drug 
concentration. 
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Fig. 5: Intra Gastric Single Layer Floating Tablet. 
2. Intra Gastric Bilayer Floating Tablets: 
These are also compressed tablet as shown in Fig 6 and containing two layer i.e.,  
i. Immediate release layer and 
ii. Sustained release layer. 
 
Fig. 6: Intra Gastric Bilayer Floating Tablet. 
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3. Multiple Unit type floating pills: 
These system consist of sustained release pills as ‘seeds’ surrounded by 
double layers. The inner layer consist of effervescent agents while the outer layer is 
of swellable membrane layer. When the system is immersed in dissolution medium 
at body temp, it sinks at once and then forms swollen pills like balloons, which float 
as they have lower density. This lower density is due to generation and entrapment 
of CO2 within the system. 
 
 
Fig. 7: (a) A multi-unit oral floating dosage system. (b) Stages of floating 
mechanism: (A) penetration of water; (B) generation of CO2 and floating; (C) 
dissolution of drug. Key: (a) conventional SR pills; (b) effervescent layer; (c) 
swellable layer; (d) expanded swellable membrane layer; (e) surface of water in 
the beaker (370C). 
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II. Volatile Liquid / Vacuum Containing Systems: 
1. Intragastric Floating Gastrointestinal Drug Delivery System: 
These system can be made to float in the stomach because of floatation 
chamber, which may be a vacum or filled with air or a harmless gas, while drug 
reservoir is encapsulated inside a microprous compartment, as shown in Fig.8. 
 
Fig. 8: Intra Gastric Floating Gastrointestinal Drug Delivery Device 
2. Inflatable Gastrointestinal Delivery Systems: 
In these systems an inflatable chamber is incorporated, which contains liquid 
ether that gasifies at body temperature to cause the chamber to inflate in the 
stomach. These systems are fabricated by loading the inflatable chamber with a drug 
reservoir, which can be a drug impregnated polymeric matrix, then encapsulated in a 
gelatin capsule. After oral administration, the capsule dissolves to release the drug 
reservoir together with the inflatable chamber. The inflatable chamber automatically 
inflates and retains the drug reservoir compartment in the stomach. The drug 
continuously released from the reservoir into the gastric fluid. 
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This system is shown in Fig. 9. 
 
Fig. 9: Inflatable Gastrointestinal Delivery System 
3. Intragastric Osmotically Controlled Drug Delivery System: 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule 
quickly disintegrates to release the intragastirc osmotically controlled drug delivery 
device. The inflatable support inside forms a deformable hollow polymeric bag that 
contains a liquid that gasifies at body temperature to inflate the bag. The osmotic 
pressure controlled drug delivery device consist of two components; drug reservoir 
compartment and an osmotically active compartment. 
The drug reservoir compartment is enclosed by a pressure responsive 
collapsible bag, which is impermeable to vapour and liquid and has a drug delivery 
orifice. The osmotically active compartment contains an osmotically active salt and 
is enclosed within a semipermeable housing. In the stomach, the water in the GI 
fluid is continuously absorbed through the semipermeable membrane into 
osmotically active compartment to dissolve the osmotically active salt. An osmotic 
pressure is thus created which acts on the collapsible bag and in turn forces the drug 
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reservoir compartment to reduce its volume and activate the drug reservoir 
compartment to reduce its volume and activate the drug release of a drug solution 
formulation through the delivery orifice. 
The floating support is also made to contain a bioerodible plug that erodes 
after a predetermined time to deflate the support. The deflated drug delivery system 
is then emptied from the stomach. This system is shown in Fig. 10. 
 
Fig. 10: Intragastric Osmotically Controlled Drug Delivery System 
B. NON EFFERVESCENT SYSTEMS: 
The Non-effervescent FDDS based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in 
non-effervescent FDDS are gel forming or highly swellable cellulose type 
hydrocolloids, polysaccharides and matrix forming material such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as well as bioadhesive polymer such as 
chitosan and carbopol. The various types of this system are as: 
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1. Single Layer Floating Tablets: 
They are formulated by intimate mixing of drug with a gel-forming 
hydrocolloid, which swells in contact with gastric fluid and maintain bulk density of 
less than unity. The air trapped by the swollen polymer confers buoyancy to these 
dosage forms. 
2. Bilayer Floating Tablets: 
A bilayer tablet contain two layer one immediate release layer which release 
initial dose from system while the another sustained release layer absorbs gastric 
fluid, forming an impermeable colloidal gel barrier on its surface, and maintain a 
bulk density of less than unity and thereby it remains buoyant in the stomach. 
3. Alignate Beads: 
Multi unit floating dosage forms were developed from freeze-dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by 
dropping a sodium alginate solution into aqueous solution of calcium chloride, 
causing precipitation of calcium alginate leading to formation of porous system, 
which can maintain a floating force for over 12 hours. When compared with solid 
beads, which gave a short residence time of 1 hour, these floating beads gave a  
prolonged residence time of more than 5.5 hour. 
4. Hollow Microspheres: 
Hollow microspheres (microballoons), loaded with drug in their outer 
polymer shells were prepared by a novel emulsion-solvent diffusion method. The 
ethanol:dichloromethane solution of the drug and an enteric acrylic polymer was 
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poured into an agitated aqueous solution of PVA that was thermally controlled at 
400C. The gas phase generated in dispersed polymer droplet by evaporation of 
dichloromethane formed an internal cavity in microsphere of polymer with drug. 
The microballoons floated continuously over the surface of acidic dissolution 
media containing surfactant for more than 12 hours in vitro. 
1.6   Factors Controlling Gastric Retention Time of Dosage Form:29 
The gastric retention time (GRT) of dosage form is controlled by several 
factors, that affect their efficacy as a gastroretentive system. 
• Density – GRT is a function of dosage form buoyancy that is dependent on the 
density.30 
• Size – Dosage form units with a diameter of more than 9.5mm are reported to 
have an increased GRT.31 
• Shape of dosage form – Tetrahedron and ring-shaped devices with a flexural 
modulus of 48 and 22.5 kilopounds per square inch (KSI) are reported to have 
better GRT. 90% to 100% retention at 24 hours compared with other shapes. 
• Single or multiple unit formulation – Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to 
failure of units, allow co-administration of units with different release profiles 
or containing incompatible substances and permit a larger margin of safety 
against dosage form failure compared with single unit dosage forms. 
• Fed or unfed state – Under fasting conditions, the GI motility is characterized 
by periods of strong motor activity or the migrating myoelectric complex 
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(MMC) that occurs every 1.5 to 2 hours. The MMC sweeps undigested 
material from the stomach and, if the timing of administration of the 
formulation coincides with that of the MMC, the GRT of the unit can be 
expected to be very short. However, in the fed state, MMC is delayed and GRT 
is considerably longer. 
• Nature of meal – Feeding of indigestible polymers or fatty acid salts can 
change the motility pattern of the stomach to a fed state, thus decreasing the 
gastric emptying rate and prolonging drug release.32 
• Caloric content – GRT can be increased by four to 10 hours with a meal that is 
high in proteins and fats. 
• Frequency of feed – The GRT can increase by over 400 minutes when 
successive meals are given compared with a single meal due to the low 
frequency of MMC. 
• Gender – Mean ambulatory GRT in males (3.40.6 hours) is less compared 
with their age and race-matched female counterparts (4.61.2 hours), 
regardless of the weight, height and body surface. 
• Age – Elderly people, especially those over 70, have a significantly longer 
GRT. 
• Posture – GRT can vary between supine and upright ambulatory states of the 
patient.33 
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• Concomitant drug administration – Anticholinergics like Atropine and 
Propantheline, opiates like Codeine and prokinetic agents like Metoclopramide 
and Cisapride. 
• Biological factors – Diabetes and Crohn’s disease. 
1.7    Advantages of FDDS: 
Floating dosage systems form important technological drug delivery systems 
with gastric retentive behavior and offer several advantages in drug delivery. These 
advantages include: 
1. Improved drug absorption, because of increased GRT and more time spent by 
the dosage form at its absorption site. 
2. Controlled delivery of drugs. 
3. Delivery of drugs for local action in the stomach. 
4. Minimizing the mucosal irritation due to drugs, by drug releasing slowly at 
controlled rate. 
5. Treatment of gastrointestinal disorders such as gastro-esophageal reflux. 
6. Simple and conventional equipment for manufacture. 
7. Ease of administration and better patient compliance. 
8. Site-specific drug delivery. 
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Disadvantages of FDDS:34 
1. Gastric retention is influenced by many factors such as gastric motility, pH and 
presence of food. These factors are never constant and hence the buoyancy 
cannot be predicted. 
2. Drugs that cause irritation and lesion to gastric mucosa are not suitable to be 
formulated as floating drug delivery systems. 
3. High variability in gastric emptying time due to its all or non-emptying process. 
4. Gastric emptying of floating forms in supine subjects may occur at random and 
becomes highly dependent on the diametral size. Therefore patients should not 
be dosed with floating forms just before going to bed. 
List of Drugs along with Floatable Drug Delivery Systems: 
SR. 
NO. 
DOSAGE 
FORM 
DRUGS 
1 Microspheres Aspirin, Grisiofulvin, p-nitroanilline, Ibuprofen, Terfinadine, 
Tranilast. 
2 Granules Diclofenac sodium, Indomethacin, Predmisolone 
3 Films Cinnarizine 
4 Powders Several basic drugs 
5 Capsules Chlordiazepoxide HCl, Diazepam, Furosemide, 1- 
Dopa,  benserazide,  Misoprostol,  Propranolol  HCl, 
Ursodeoxycholic acid 
6 Tablets/pills Acetaminophen, Acetylsalisylic acid, Amoxicillin trihydrate, 
Ampicillin,  Atenolol,  Chlorpheniramine,  Cinnazirine, 
Diltiazem, Fluorouracil, Isosorbide mononitrate, Isosorbide 
dinitrate, p-aminobenzoic acid, Piretanide, Prednisolone, 
Quinidine gluconate, Riboflavin-5-phosphate, Sotalol, 
Theophylline, Verapamil HCl 
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1.8    Marketed Products of FDDS: 
SR. 
NO. 
BRAND 
NAME 
DRUG (DOSE) COMPANY, 
COUNTRY 
REMARKS 
1. ® Modapar Levodopa (100 mg), 
Benserazide (25 mg) 
Roche Products, 
USA 
Floating CR 
capsule 
2. ® Valrelease Diazepam (15 mg) Hoffmann-
LaRoche, USA 
Floating 
capsule 
3. Liquid 
® Gavison 
Al hydroxide (95 
mg), Mg carbonate  
(358 mg) 
Glaxo Smith 
Kline, India 
Effervescent 
floating liquid 
alginate 
preparation 
4. ® Topalkan Al-Mg antacid Pierre Fabre 
Drug, France 
Floating liquid 
alginate 
preparation 
5. Conviron Ferrous sulphate Ranbaxy, India Colloidal gel 
Forming FDDS 
6. ® Cifran OD Ciprofloxacin  
(1 gm) 
Ranbaxy, India Gas-generating 
floating tablet 
7. ® Cytotec Misoprostal (100 
mcg/200 mcg) 
Pharmacia, 
USA 
Bilayer floating 
capsule 
8. Oflin OD® Ofloxacin (400mg) Ranbaxy, India Gas generating 
floating tablet 
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Disease Profile 
In the present study Clarithromycin is taken as a model drug for the 
development of formulation of Hydrodynamically balanced tablets. Clarithromycin 
is one of the main antibiotic in the first line treatment of H.pylori infection. 
H.pylori is the most common bacterial pathogen responsible for causing 
peptic ulcer and gastritis. Helicobacter pylori is a motile, aerobic, S-shaped 
bacterium that is typically found in the gastric epithelium of the antrum. The 
organism possesses flagellae that are important in its ability to penetrate the mucus 
layer of gastric mucus. It produces a powerful urease that generates an alkaline 
microenvironment to survive gastric acidity. 
 
Fig. 11: Schematics of H.pylori location within the stomach. 
The eradication of H.pylori is limited by its unique characteristics i.e. it 
penetrates the gastric mucus layer and fixes itself to various phospholipids and 
glycolipids on epithelial surface. Thus the microorganism exclusively resides on the 
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luminal surface of the gastric mucosa under the mucus gel layer in the acidic 
environment of the gut. H.pylori is equipped with catalase and urease enzymes, 
which breakdown urea into bicarbonate and ammonia and thus in turn protects the 
bacterium in the acid milieu of stomach vis-à-vis leads to gastric epithelial injury.35 
For effective treatment of H.pylori infection, therapeutic agents have to 
penetrate the gastric mucus layer to disrupt and resist the mechanism of 
colonization,36,37 which needs targeted drug delivery within the stomach 
environment. 
This stomach-specific delivery system will increase the gastric residence 
time, decrease the diffusional distance, and allow more of the antibiotic to penetrate 
through the gastric mucus layer and act locally at the infectious site. 
By increasing the local concentration and contact time, stomach specific 
delivery system also minimize the resistance problems associated with systemic 
administration of antibiotics.38,39,40 
Classifiction Of Antibacterial: 
i) Antibacterial are classified in many ways based on chemical structure;its spectrum 
of activity;Pharmacological activity. 
a) β-lactum antibiotic:eg.penicillins,Cephalosporins, 
b) Aminoglycosideantibiotics:eg.Neomycin,Streptomyci 
c) Tetracyclines:eg.Tetracycline,Oxytetracycline. 
d) Macrolide antibiotics:eg.Clarythromycin,Erythromycin. 
e) Lincomycin:eg.Lincomycin,Clindamycin 
f) miscellaneous:eg.Novobiocin,Chloramphenicol. 
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ii) Based on pharmacological activity 
            a)Antifungal antibiotics. 
                        i)Polyene:eg.amphotericin B, nystain. 
                        ii)others:eg.Griseofulvin. 
             b)anticancer Antibiotics:eg.Streptozocin,Valrubicin. 
             c)Antityphoid antibiotic:eg.Chloramphenicol. 
             d)Antidiarrheal antibiotic:eg.Colistin 
             e)Antituberculer antibiotic:eg.Rifampicin,Cycloserine. 
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2. REVIEW OF LITERATURE 
REPORTED FLOATING DRUG DELIVERY SYSTEMS 
A lot of work has been done on the development of floating drug delivery 
system. Some of them are cited below. 
Ichikawa M, et al.47 reported a multiple unit type of floating dosage form 
containing Aminobenzoic acid for which the floating ability and sustained release 
characteristics were evaluated in-vitro. The system was floating completely within 
ten minutes and about 80% remained floating over 5 hours, irrespective of pH and 
viscosity of the buffer medium used, and followed zero order drug release. 
Floating force kinetics of peroral polymeric matrix dosage forms by a novel 
in-vitro resultant-weight measuring system were reported by  
Timmermans J. et al.48 showed that bulk density of dosage form was not the most 
appropriate parameter for describing its buoyancy capabilities. These capabilities 
were perfectly represented and monitored by resultant weight measurements. 
Results indicated that the magnitude of floating strength may vary as a 
function of time and usually decreases after immersion of the dosage form into the 
fluid consequently to the evolution of its hydrodynamic equilibrium. 
Baumgartner S, et al.49 developed floating matrix tablets containing 
Hydroxypropyl Methyl Cellulose, which after oral administration are designed to 
prolong the gastric residence time, increase the bioavailability and diminish the  side 
effects of irritating drugs. The importance of the composition optimization, the 
formulation aspects and characterization of the tablets were examined. The 
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investigation showed that the tablet composition and mechanical strength have great 
influence on the floating and drug release properties of the tablets. They concluded 
that the drug release from the tablets followed non-Fickian transport. 
Roughe N, et al.50 conducted a study to evaluate the factors that improves 
the in vitro buoyancy and drug release profile of floating minitablets containing 
either Piretinide or Atenolol as the model drug. The buoyancy of the minitablets was 
achieved either by the swelling of the excipients or by incorporating gas generating 
agent, sodium bicarbonate. The study concluded that it is possible to produce 
minitablets containing either Piretinide or Atenolol, which have a positive resultant 
weight during more than 6 hr and satisfactory release profiles. 
Ingani HM, et al.51 described the formulation, dissolution, buoyancy and in 
vivo release tests of a double layer, sustained release Riboflavin phosphate sodium 
hydrophosphate matrix oral tablet containing a carbon dioxide generating layer. 
The in vivo behavior of this floating tablet was then compared to a classical 
hydrodynamically balanced capsule system. The floating dosage forms had 
increased residence time as compared to the non-floating tablet. 
Menon A, et al.52 reported the formulation of a monolithic floating dosage 
form for Furosemide using factorial design keeping the drug to polymer ratio, 
polymer to polymer ratio and polymer grade as the three factors. The optimized 
formulation thus obtained was found to have a good in vitro / in vivo correlation. 
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Shoufeng Li, et al.53 developed an optimized gastric floating drug delivery 
system for oral controlled delivery of Calcium. A central, composite Box-Wilson 
design for the controlled release of calcium was used with three formulation 
variables; 
HPMC loading, citric acid loading and magnesium stearate loading. All three 
formulation variables were found to significantly effect release properties. Only 
HPMC loading was found to be significant for floating properties.  
Hilton AK, et al.54 fabricated an oral sustained release floating tablets of 
Amoxycillin trihydrate and carried out the in vitro – in vivo evaluation. From the 
studies, it shows that the drug slowly released in the stomach by diffusion from the 
floating matrix tablet and then trickle towards the proximal intestine where 
absorption occurs. It improved the delivery of antibiotic resulting in more uniform 
levels of antibiotic following less frequent oral dosing. 
Ozdemir N, et al.55 developed floating bilayer tablet of Furosemide-
cyclodextrin inclusion complex. They determined the gastric residence time 
using radiographs by adding BaSO4 and reported that the tablet stayed in stomach 
for 6 hours. Also the bioavailability of Furosemide from floating tablet was about 
1.8 times those of the conventional tablet and also significant in vitro – in vivo 
correlation was detected. 
Jimenez-Castellanos, et al.22 designed and tested the in vitro floating and 
bioadhesive property of Sotalol for oral application. Tablets were prepared by 
mixing the active ingredient with Sodium carboxy methyl cellulose, Hydroxy propyl 
cellulose and a carbonate to generate gas. In vitro tests for release of drug, floatation 
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and bioadhesion of the tablets were carried out. They concluded that this system 
showed good characteristics for controlled drug delivery system.  
El-Kamel.56 developed a sustained release system for Ketoprofen to increase 
its residence time in the stomach without contact with the mucosa and was achieved 
through the preparation of floating microparticles by the emulsion solvent diffusion 
technique. All the floating microparticle formulation were evaluated for flow 
properties, packability and drug release rate. 
Joseph NJ, et al.57 studied the effect of solvent evaporation technique on 
floating type hollow polycarbonate microsphere of Piroxicam which were capable of 
floating on simulated gastric fluid. Pharmacokinetic analysis showed that the 
bioavailability of Piroxicam hollow microsphere was about 1.4 times that of free 
drug and was about 4.3 times for the dosage form consisting of microsphere plus the 
loading dose. The elimination half life was increased by three times that of free  
drug. 
Park, et al.58 developed and evaluated floating beads from Sodium Alginate 
solution containing CaCO3 or NaHCO3 as gas-forming agents with Riboflavin as a 
model drug. In vitro release studies revealed that CaCO3 is superior to NaHCO3 as 
gas forming agent in alginate bead preparations, with enhanced buoyancy and 
sustained release properties making them excellent for floating drug delivery system. 
Burns SJ, et al.59 reported an in-vitro dissolution method for a floating 
dosage form with biphasic release characteristics. A modified paddle dissolution for 
the evaluation of Propranolol in a floating dosage form that demonstrates both rapid  
and sustained release properties were reported. 
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Machida S, et al,60 fabricated two drug formulations which floated in gastric 
juice. One, a buoyant tablet, consisted of powdered Soyabean protein, drug and 
Sodium bicarbonate. The other, a laminated film type preparation consisted of a 
drug film, an effervescing film containing Sodium bicarbonate and outer drug 
release regulating time. Cinnarazine, an acid soluble drug was used as the model 
drug. 
Deshpande AA, et al.21 developed novel controlled release gastric retention 
system, which consists of a matrix tablet, coated with a permeable membrane. 
Tablets containing soluble drug Chlorpheniramine maleate and poorly soluble drug 
Riboflavin were compressed. Studies showed that, the chances of elimination 
through the pylorus greatly reduced due to tablets expansion and the tablet expelled 
out of stomach at the end of the drug release. 
Blanquet S, et al.61 developed a dynamic artificial gastrointestinal system 
for studying the behaviour of orally administered drug dosage form under various 
physiological conditions. It was studied using two model drugs Paracetamol and 
Acetaminophen. The results concluded that the in-vitro results were consistent with 
in vivo data. 
Shah S, et al.62 developed stomach specific drug delivery for treatment of 
Helicobacter pylori consisted of Tetracycline loaded chitosan microsphere which 
release drug for a period of 12 hr residing the dosage form in stomach due to 
inherent properties of chitosan to form a gel in acidic medium as well as bioadhesion 
characteristics. 
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Alderete ME, et al.63 prepared matrix tablets of Metranidazole with HPMC 
viscosity ranging from 15cps to 30,000 cps and particle size ranging from 163m 
to 505m. There was a linear relationship between the inverse of release rate and 
viscosity grade at polymer concentration of 10%. A linear relationship between the 
release rate and cube of the diameter particle size also determined. 
El-Gibaly64 formulated and compared chitosan floating microcapsules 
containing Melatonin with conventional non-floating Chitosan microspheres. 
Floating microcapsules showed zero order release kinetics and more than 12 hrs 
floating time in vitro. Moreover, these floating microcapsules greatly retarded the 
drug release lasting for several hours while it was almost instant from conventional 
microspheres. 
A new intragastric delivery system for the treatment of H.pylori associated 
gastric ulcer was developed by yang and hejazi They developed intragastric 
floating drug delivery system by using HPMC K4M, Chitosan and found that the 
developed delivery system has potential to increase the efficacy of the therapy and 
improve patient compliance. 
Bhat SS, et al.65 developed Clarithromycin sustained release tablet for 
improved efficacy. They observed that, in sustained release formulation, the 
concentration of antibiotic is far greater than MIC and reduced the drug resistance. 
Statistical analysis showed that drug release from the tablet matrix followed zero 
order kinetics. 
Pharmacokinetic parameters of Clarithromycin and its metabolite were 
studied by 
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 Scaglione et al.66 and found that maximum serum concentrations were 
reached within 3 hours irrespective of ethnic origin and regardless of the dose. The 
presence of food have no clinical effect on Clarithromycin pharmacokinetic 
properties. 
Darkes MJM, et al.67 developed Clarithromycin extended release tablet. It 
showed that maximum plasma concentration are lower and reached later with 
extended-release tablets than with the immediate release tablets. 
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3.  AIM AND OBJECTIVE 
H.pylori is currently the single most common cause of peptic ulcer 
worldwide, accounting for 80% gastric ulcer and up to 95% of duodenal ulcers. 
Antimicrobial therapy is most acceptable choice of treatment for patients with active 
gastric or duodenal ulcers who are infected with H.pylori.  
Although H.pylori is sensitive to antimicrobial agents in-vitro, successful 
treatment of infection is challenging due to its unique. Characteristics, i.e., the 
bacterium tends to inhabit the gastric mucous gel and hence access for antimicrobial 
drug to the site of infection is restricted, both from the lumen of the stomach and 
from the gastric blood supply. 
Therefore for effective treatment, the therapeutic agents have to penetrate the 
gastric mucus layer to disrupt the mechanism of colonization, within the stomach 
environment. One way to improve the efficacy of eradicating H.pylori infection is to 
deliver the antibiotic locally to the stomach.  
This goal can be achieved by the development of hydrodynamically balanced 
system or floating drug delivery system which increases the gastric residence time, 
decreases the diffusional distance and allow more of the antibiotic to penetrate 
through the gastric mucus layer and act locally at the infectious site. Clarithromycin 
is one of the first line antibiotic in the treatment of H.pylori infection along with 
Amoxycillin and Omeprazole. 
The present study outlines a systematic approach for design and development 
of hydrodynamically balanced tablets of clarithromycin to enhance the 
bioavailability and therapeutic efficacy of the drug. 
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OBJECTIVE OF THE STUDY 
• Design and development of the Hydrodynamically balanced tablets of 
Clarithromycin. 
• To study the effect of different polymers on the drug release. 
• Evaluation of the prepared formulation for physicochemical properties and 
drug release profile. 
• Analyse the drug release data for kinetic equations. 
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4.   PLAN OF WORK 
 
1.     Preformulation Study 
• Organoleptic properties 
• Solubility 
• Determination of melting point 
• Compressibility index 
• pH 
• Loss on drying 
2.      Evaluation of Powders   
• Angle of repose  
• Bulk density  
• Tapped density  
• Powder flow Properties  
3.     Compression of powders into tablet 
4.    Tablet evaluation  
• Thickness  
• Hardness  
• Friability  
• Uniformity of weight  
• Drug content 
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• Tablet density  
• In vitro buoyancy studies 
• In vitro dissolution 
5.     Kinetic Studies 
6.     Stability Studies 
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5.  PROFILE 
5.1     DRUG PROFILE  
CLARITHROMYCIN41,42 
Structure: 
 
Chemical Name : 6-O-methylerythromycin 
Empirical formula : C38H69NO13 
Molecular Weight : 747.95 
Melting Point : 2200C 
Description : White or colourless, odourless crystals. 
Category : Antibacterial 
Storage : Store in a cool, dry place. 
Solubility: 
It is soluble in chloroform, acetone, dilute acids. Slightly soluble in 
methanol, ethanol and acetonitrile, and practically insoluble in water. 
Chapter 5  Drug Profile 
 
Dept. of Pharmaceutics 42 JKK Nattraja College of Pharmacy 
 
Pharmacodynamic Property: 
Clarithromycin is a semi-synthetic broad spectrum macrolide antimicrobial 
agent structurally related to Erythromycin. It is acid stable and rapidly absorbed after 
oral administration. 
Clarithromycin is bacteriostatic or bacteriocidal depending on the organism 
and antimicrobial agent concentration. It exerts its antibacterial action by binding to 
the 50S ribosomal sub-unit of susceptible bacteria and suppresses protein synthesis. 
It is highly potent against wide variety of aerobic and anaerobic gram-positive and 
gram-negative organisms such as S.aureus, S.pneumoniae, H.influenza, Moraxella 
catarrhalis, and other microorganisms like Mycobacterium avium complex (MAC) 
and Helicobacter pylori. 
Pharmacokinetic Property: 
Absorption:- Clarithromycin is absorbed rapidly from the gastrointestinal 
tract after oral administration. The microbiologically active metabolite 14-hydroxy 
Clarithromycin is formed by first pass metabolism. Peak concentration occurs 
approximately 2 hrs after drug administration. Steady state peak concentration in 
plasma are 2 to 3 mg/ml after 2 hours from a regimen of 500mg every 12 hours or 2 
to 4 hours after two 500mg extended release tablets given orally. 
Distribution:- 
Clarithromycin and  its active  metabolite 14-hydroxy Clarithromycin 
distribute widely throughout the body and achieve high intracellular concentrations. 
Tissue concentrations generally exceed serum concentrations. Concentrations in 
middle ear fluid are 50% higher than simultaneous serum concentrations for both 
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Clarithromycin and the active metabolite. Protein binding of Clarithromycin ranges 
from 40-70%. 
Elimination:- 
Clarithromycin is eliminated by renal and non-renal mechanisms. It is 
metabolized in the liver to active 14-hydroxy metabolite. The elimination half-lives 
of Clarithromycin and 14-hydroxyclarithromycin are approximately 3 to 7 hours and 
5 to 9 hours. The amount of Clarithromycin excreted unchanged in the urine ranges 
from 20% to 40% depending on the dose administered and formulation. 
Therapeutic Uses: 
• Used in combination for the treatment of Helicobacter pylori infection and 
duodenal ulcer disease. 
• For treatment of upper and lower respiratory tract infections. 
• For prevention of disseminated Mycobacterium avium complex (MAC) 
infections in patients with advanced human immunodeficiency virus (HIV) 
infections. 
• Uncomplicated skin and skin structure infections like Folliculitis, Cellulitis, 
Erysipelas. 
Adverse Effects: 
The majority of the adverse effects reported were of mild and transient 
nature like Diarrhoea, nausea, abnormal taste, dyspepsia, headache, etc. 
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Dosage and Administration: 
Clarithromycin is used orally in a dose of 250 to 500mg twice daily. 
Marketed Preparations: 
CELEX OD (Abott) 500 mg 
Clarithro ER (Alembic) 500 mg 
URCLAR OD (Novartis) 500 mg 
MACLAR (Gracewell) 500 mg 
Mechanism Of Action: 
a) clarithromycin prevents bacteria from growing by interfering with their Protein 
synthesis. 
b)  clarithromycin binds to the subunit 50S of the bacterial ribosome  and thus 
inhibits the translation of Peptides  
c) Clarithromycin has similar antimicrobial spectrum as erythromycin but is more 
effective against certain gram-negative bacteria, particularly  Legionella 
Pneumophilla. 
d) Clarithromycin also has bactericidal effect on certain   strains such    as 
Haemophilus Influenzae, Streptococcus Pneumoniae and  Neisseria   
Gonorrhoae.      
Chapter 5  Drug Profile 
 
Dept. of Pharmaceutics 45 JKK Nattraja College of Pharmacy 
 
5.2.   POLYMER REVIEW 
5.2.1 HYDROXY PROPYL METHYL CELLULOSE43 
Non-proprietary names: 
BP : Hypromellose 
USP : Hydroxy propyl methyl cellulose 
Synonyms: 
Methyl hydroxypropyl cellulose, Propylene glycol ether of methylecellulose, 
Methylcellulose, Methylcellulose propylene glycol ether. 
Chemical Name: 
Cellulose, 2-hydroxypropyl methyl ether 
Empirical formula: 
C8H15O6 – (C10H18O6)n – C8H15O5 
Description: 
It occurs as odourless and tasteless creamy white coloured fibrous or 
glandular powder. 
Molecular weight:- 
Approximately 86,000 
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Functional category:- 
Coating agent, film former, Tablet binder, Stabilizing agent, Suspending 
agent, Viscosity increasing agent. 
Density: 
0.25 – 0.70 g/cm3 
Solubility: 
Soluble in cold water forming viscous colloidal solution, insoluble in 
Chloroform, Ethanol and Ether, but soluble in mixtures of Ethanol and Methylene 
chloride. 
Viscosity: 
HPMC K4M : 4,000 cps 
HPMC K15M : 15,000 cps 
Stability and Storage: 
It is stable although it is slightly hygroscopic. The bulk material should be 
stored in a air tight container in a cold and dry place. Increase in temperature 
reduces the viscosity of the solution. 
Safety: 
It is widely used in many oral and topical pharmaceutical formulations. It is 
generally regarded as a non-toxic and non-irritant material, although excessive 
consumption may have laxative effect. 
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Pharmaceutical Applications:  
1. Film-former in tablet film coating:  Lower viscosity grades are used in aqueous 
film coating and higher viscosity grades are used in solvent film coating. 
2. Binder in tablet granulations:  2.5% high-viscosity grades are used to retard the 
release of water-soluble drugs. 
3. As a Thickening agent:  Thickening agent added to   vehicles for eye drops & 
artificial fear solutions at 0.45 - 1.0% concentrations. 
4. As a protective colloid :  Prevents droplets and particles from                                      
5. Coalescing or agglomerating, thus inhibiting the formation of sediments. It is 
used as emulsifier, suspending agent & stabilizer in gels & ointments. As an 
adhesive in plastic bandages. 
5.2.2 CHITOSAN44,45,46 
 Chitosan is obtained by alkaline deacetylation of chitin, the most abundant 
polysaccharide in nature. The two polymers are distinguished by insolubility or 
solubility in dilute aqueous acid solution. Main source of chitin are the shell wastes 
of shrimp, lobster and crab. 
Chemical name: 
Poly(N-acetyl-2-amio-2-deoxy-D-glucopyranose) 
Molecular Weight: 
50,000 – 20,00,000 
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Category: 
Tablet binder, wetting agent, coating agent, also used in vaccine delivery, 
peptide delivery, gene delivery. 
Description: 
Odourless, tasteless, white or creamy white fibers. 
Density: 
1.35 – 1.40 g/cm3 
Solubility: 
Soluble in dilute acid solutions, insoluble in alkaline solution, water and 
most organic solvents. 
Viscosity: 
Chitosan A (49%) 
Chitosan B (66%) medium viscosity type. 
Stability and Storage: 
Stable in dry form. Store in a well closed container in a cool place. 
Safety: 
It is non-toxic, biodegradable and biocompatible. It has antiulcerogenic, 
mucoadhesive property. 
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5.3  EXCIPIENT REVIEW 
5.3.1 SODIUM BICARBONATE43 
Non-proprietary Names: 
BP/EP: Sodium bicarbonate 
Synonym: 
Baking soda, E-500, Monosodium carbonate. 
Chemical name: 
Carbonic acid, Monosodium salt, Monosodium carbonate. 
Empirical formula: NaHCO3 
Molecular weight: 84.01 
Category: 
Alkalizing agent, therapeutic agent. 
Description: 
It is an odourless, white crystalline powder with slight alkaline taste. 
Acidity/ Alkalinity: 
pH 8.3 for freshly prepared 0.1M aqueous solution at 2500C. 
Density: 
2.159 g/cm3 
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Solubility: 
Soluble in water, practically insoluble in ethanol. 
Stability and Storage: 
Sodium bicarbonate is stable in dry air but slowly decomposes in moist air 
and should therefore be stored in well-closed container in a cool dry place. 
Safety: 
Orally ingested sodium bicarbonate neutralizes gastric acid with the 
evolution of carbon dioxide and may cause stomach cramps and flatulence. 
5.3.2 MAGNESIUM STEARATE43 
Non-proprietary Names: 
BP: Magnesium stearate 
Synonyms: 
Metallic stearate, Magnesium salt. 
Chemical name: 
Octadecanoic acid, Magnesium salt. 
Empirical formula : C36H70MgO4 
Molecular weight : 591.27 
Category : Tablet and capsule lubricant (0.25 – 5.0%) 
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Description: 
Magnesium stearate is a fine, white, precipitated or milled, impalpable 
powder of low bulk density, the powder is greasy to touch and readily adheres to the 
skin. 
Density: 
1.03 to 1.08 g/cm3 
Solubility: 
Insoluble in ethanol (95%) and water. Slightly soluble in warm benzene and 
hot alcohol. 
Stability and storage: 
It is stable and to be stored in a well closed container in a cool dry place. 
Safety: 
Magnesium stearate is widely used as a pharmaceutical excipient and is 
generally regarded as being non-toxic following oral administration. Inhalation of 
magnesium stearate is harmful. 
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5.3.3 LACTOSE43 
Non-proprietary name: 
BP/EP : Lactose 
Synonym : Milk sugar, Saccharum lactis. 
Chemical name : 4-O-â-D-galactopyranosyl-á-D-glucopyranose 
  4-(â-D-galactoside)-D-glucose 
Empirical formula : C12H22O11 
  C12H22O11H20 
Molecular weight : 342.30 – 360.31 
Category : Filler and diluent 
Description: 
White to off white or creamy white crystalline particles or powder, 
odourless, sweet tasting. 
Solubility: 
Freely soluble in water, practically insoluble in chloroform, ethanol and 
ether. 
Stability and Storage: 
Store in a well-closed container to prevent absorption of moisture and 
odours. Under humid conditions mold growth may occur. Lactose may develop 
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brown colouration on storage. This reaction is accelerated by warm-damp 
conditions. 
Safety: 
Adverse reactions to lactose is largely attributed to lactose intolerance, which 
occurs in persons with a deficiency of the intestinal enzyme lactose. 
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6. MATERIALS AND METHODS 
6.1.1  Materials used 
The following materials that were either AR/LR grade or the best possible 
pharma grade available were used as supplied by the manufacturer 
Sr. 
No. 
Materials Suppliers 
1. Clarithromycin Microlabs Ltd. Hosur  
2. HPMC K4M Microlabs Ltd. Hosur 
3. HPMC K15M Microlabs Ltd. Hosur 
4. Chitosan Microlabs Ltd. Hosur 
5. Sodium bicarbonate Microlabs Ltd. Hosur 
6. Lactose (Monohydrate) Microlabs Ltd. Hosur 
7. Magnesium Stearate Microlabs Ltd. Hosur 
8. Hydrochloric Acid Microlabs Ltd. Hosur 
 
6.1.2   Detailed Of instrument used 
1. Electronic Balance Shimadzu ELB-300 
2. Hardness Tester Swastik 
3. Friability test apparatus Roche Friabilator 
4. Hydraulic Press Kimaya Engineers 
5. Dial Caliper Mitutoyo, Japan. 
6. Tablet Dissolution Tester (USPXX III) Lab India, Lambda 25 
7. Tap Density Tester Lab India, Lambda 25 
8. UV Spectrophotometer Lab India, Lambda 25 
9. FTIR Spectrophotometer Cat j. shimadzu 
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6.2    Preformulation Studies  
It is one of the important prerequisite in development of any drug delivery 
system.preformulation studies were performed on the drug, which included 
solubility, melting point, Flow properties,compatibility studies. 
a) Solubility 
Solubility of Clarythromycin was determined in ethanol (95%), Chloroform, 
acetone,ether,and 0.1 N HCL.Solubility studies were performed by taking excess 
amount of Clarythromycin in different beakers containing the solvent. The mixture 
were shaken for 10 hrs at regular intervals. The solution were filtered by using 
Whatmanns filter paper grade no 41. The filtered solution were analysed 
Spectrophotometrically. 
b) Melting point 
Melting point of the clarythromycin was determined by capillary method. 
c)     Flow properties 
a) Angle of Repose (θ): 
The frictional forces in a loose powder or granules can be measured by angle 
of repose. This is the maximum angle possible between the surface of a pile of 
powder or granules and the horizontal plane. 
The granules were allowed to flow through the funnel fixed to a stand at 
definite height (H). The angle of repose was then calculated by measuring the height 
and radius of the heap of granules formed. 
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tanθ = h/r 
θ = tan-1 (h/r) 
where θ = angle of repose 
h = height 
r = radius 
b) Compressibility Index: 
The flowability of powder can be evaluated by comparing the bulk density 
(Do) and taped density (Df) of powder and the rate at which it packed down. 
Compressibility index is calculated by – 
Compressibility index (%) = 
Df
DoDf − X 100 
Where 
Do = Bulk density 
Df = Tapped density 
c)  Compatibility Studies: 
They provide framework for the drug in combination with the excipients in 
the fabrication of the dosage form and establish that active drug has not undergone 
degradation. This can be confirmed by carrying out infrared light absorption 
scanning spectroscopy. 
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I.R. Studies: 
It is one of the most powerful analytical technique for chemical identification 
of drug. 
Method:- The pure drug and its formulation were subjected to IR studies. In 
the present study, the potassium bromide disc (pellet) method was employed 
6.2.1  Preparation of Standard Calibration Curve:68 
The calibration curve was obtained by dissolving Clarithromycin in 0.1N 
Hydrochloric acid and further dilutions were made using 0.1N Hydrochloric 
acid and absorbance measured spectrometrically at 203nm. Beer’s Law was obeyed 
in the concentration range of 20-120μg/ml. 
Method: 
Standard stock solution:- 
The stock solution was freshly prepared by weighing specified amount of 
Clarithromycin in 100ml volumetric flask. The drug was dissolved in and diluted to 
volume with 0.1N hydrochloric acid. 
Preparation of Calibration Curve:- 
The aliquots of standard solution were taken in a series of 50ml of 
volumetric flasks. The mixtures were properly shaken. The resulting samples were 
ready to form the calibration curve. 
The absorbance values were measured at 203nm against reference blank, 
plotted against concentration to obtain the standard calibration curve. 
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6.2.2.   Formulation of Hydrodyamically Balanced Tablets: 
Floating matrix tablets containing Clarithromycin were prepared by direct 
compression technique using varying concentrations of different grades of polymers 
with sodium bicarbonate. 
All the ingredients except magnesium stearate were blended in glass mortar 
uniformly. After sufficient mixing of drug as well as other components, magnesium 
stearate was added and further mixed for additional 2-3 minutes. The tablets were 
compressed with 13mm punch using hydraulic press. The weight of the tablets was 
kept constant for formulations F1 to F10. The composition of all formulations was 
given in Table 1. 
6.2.3   Evaluation of Hydrodynamically Balanced Tablets: 
Evaluation was performed to assess the physicochemical properties and 
release characteristics of the developed formulations. 
6.2.4  Evaluation of granules  
a) Angle of Repose (θ): 
The frictional forces in a loose powder or granules can be measured by angle 
of repose. This is the maximum angle possible between the surface of a pile of 
powder or granules and the horizontal plane. 
The granules were allowed to flow through the funnel fixed to a stand at 
definite height (H). The angle of repose was then calculated by measuring the height 
and radius of the heap of granules formed. 
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tanθ = h/r 
θ = tan-1 (h/r) 
where θ = angle of repose 
h = height 
r = radius 
b) Compressibility Index: 
The flowability of powder can be evaluated by comparing the bulk density 
(Do) and taped density (Df) of powder and the rate at which it packed down. 
Compressibility index is calculated by – 
Compressibility index (%) = 
Df
DoDf − X 100 
Where 
Do = Bulk density 
Df = Tapped density 
6.2.5  Evaluation of tablet 
a) Shape of Tablets: 
Directly compressed tablets were examined under the magnifying lens for 
the shape of the tablet. 
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b) Tablet Dimensions:71 
Thickness and diameter were measured using a calibrated dial caliper. Three 
tablets of each formulations were picked randomly and thickness was measured 
individually. 
C) Thickness  
The dimensions of the tablet like thickness, length were measured using 
vernier-calipers. Ten tablets were selected randomly for this test and the average 
value was reported. 
d) Hardness:71 
Hardness indicates the ability of a tablet to withstand mechanical shocks 
while handling. The hardness of the tablets were determined using Monsanto 
hardness tester. It is expressed in kg/cm2. Three tablets were randomly picked and 
hardness of the same tablets from each tablets was determined. 
e) Friability test: 
The friability of tablets were determined using Roche Friabilator. It is 
expressed in percentage (%). Ten tablets were initially weighed (Winitial) and 
transferred into friabilator. The friabilator was operated at 25rpm for 4 minutes or 
run up to 100 revolutions. The tablets were weighed again (Wfinal). The % friability 
was then calculated by – 
F = 
initialW 
finalW -initialW  X 100 
% Friability of tablets less than 1% are considered acceptable. 
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f) Weight Variation Test:71 
Ten tablets were selected randomly from each batch and weighed 
individually to check for weight variation. A little variation is allowed in the weight 
of a tablet by U.S. Pharmacopoeia. The following percentage deviation in weight 
variation is allowed. 
In all formulations, the tablet weight is more than 324mg, hence 5% 
maximum difference allowed. 
Average weight of a tablet Percentage deviation 
130 mg or less 10 
>130mg and <324mg 7.5 
324 mg or more 5 
 
g) Test for Content Uniformity:68 
Tablet containing 500mg of drug is dissolved in 100ml of 0.1N HCl taken in 
volumetric flask. The drug is allowed to dissolve in the solvent. The solution was 
filtered, 1ml of filtrate was taken in 50ml of volumetric flask and diluted up to mark 
with 0.1N HCl and analysed spectrophotometrically at 203nm. The concentration of 
Clarithromycin in mg/ml was obtained by using standard calibration curve of the 
drug. Claimed drug content was 500mg per tablet. Drug content studies were carried 
out in triplicate for each formulation batch. 
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h) Tablet Density:73 
Tablet density is an important parameter for floating tablets. The tablet will 
only float when its density is less than that of gastric fluid (1.004). The density was 
determined using following relationship. 
V =πr2h 
d = m/v 
v = volume of tablet (cc) 
r = radius of tablet (cm) 
h = crown thickness of tablet (g/cc) 
m = mass of tablet 
i) Buoyancy / Floating Test:74 
The time between introduction of dosage form and its buoyancy on the 
simulated gastric fluid and the time during which the dosage form remain buoyant 
were measured. The time taken for dosage form to emerge on surface of medium 
called Floating Lag Time (FLT) or Buoyancy Lag Time (BLT) and total duration of 
time by which dosage form remain buoyant is called Total Floating Time (TFT). 
j) Swelling Study:75 
The swelling behaviour of a dosage form is measured by studying its weight 
gain or water uptake. The dimensional changes can be measured in terms of the 
increase in tablet diameter and/or thickness over time. Water uptake is measured in 
terms of percent weight gain, as given by the equation. 
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WU = 
W0
W0- W1  X 100 
Wt = Weight of dosage form at time t. 
W0 = Initial weight of dosage form 
k) Effect of hardness on Buoyancy Lag Time (BLT) or Floating Lag Time 
(FLT):77 
Formulation F2 was selected to study the effect of hardness on buoyancy lag 
time. The tablets of batch F2 were compressed at three different compression 
pressures to get the hardness of 5kg/cm2, 7kg/cm2 and 9kg/cm2. The tablets were 
evaluated for Buoyancy Lag Time. The method followed is same as that of 
Buoyancy test. 
l) In-vitro Dissolution Study:-76 
In-vitro release studies were carried out using USP XXIII dissolution test 
apparatus. 900ml of 0.1N HCl (pH 1.2) was filled in dissolution vessel and the 
temperature of the medium was set at 370C+0.100C. For the study ring/mesh 
assembly was used. The tablet was put inside the ring assembly and placed inside 
the dissolution vessel. The speed was set at 50 rpm. 1ml of sample was withdrawn at 
predetermined time intervals for 10 hours and same volume of fresh medium was 
replaced. The samples were analyzed for drug content against 0.1N HCl as a blank 
atλmax 203nm using U.V. spectrophotometer. 
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m) Curve fitting analysis: 
The mechanism of Clarithromycin released from the matrix system was 
studied by fitting the dissolution data obtained to following equation. 
1. Korsmeyer – Peppas equation 
2. Zero order equation 
3. Higuchi square root equation 
n) Comparison with commercial marketed product: 
The promising formulation was compared with marketed product 
formulation by checking various physicochemical parameters. 
o) Stability study   
The optimum formulation was tested for a period of 12 weeks at 40c with 
75% RH for drug content and other parameters. 
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7. RESULTS AND DISCUSSION 
7.1   EXPERMENTAL METHODS 
FORMULATION AND EVALUATION OF CLARYTHROMYCIN 
FLOATING TABLETS:  
All the formulations were prepared by direct compression method using 
different polymers. (designated as F-1 to F-10).  
PROCEDURE:  DIRECT COMPRESSION 
1. Clarythromycin and all other ingredients were individually passed through 
sieve ≠ 60. 
2. All the ingredients were mixed thoroughly by triturating up to 15 min. 
3. The powder mixture was lubricated with talc,Magnesium stearate. 
4. The tablets were prepared by using direct compression method. 
7.1.1  Preformulation studies 
Hydrodynamically balanced tablets of Clarithromycin were prepared and 
evaluated for their use as gastroretentive drug delivery systems to increase its local 
action and bioavailability 
In the present work total Ten formulations were prepared and complete 
composition of all batches shown in Table4. The tablets were then characterized for 
various physicochemical parameters. 
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Table No:1  preformulation Studies 
 
7.1.2. COMPATIBILITY STUDY: 
Compatibility studies were performed using IR spectrophotometer. The IR 
spectrum of pure drug and physical mixture of drug and polymer were studied. 
The characteristic absorption peaks of Clarithromycin were obtained at 
891.60cm-1, 1049.30cm-1, 1373.95cm-1, 1691.72cm-1. 
The peaks obtained in the spectras of each formulation correlates with the 
peaks of drug spectrum. This indicates that the drug is compatible with the 
formulation components. The spectras for all formulations are shown in Fig. 12 to 
Fig. 14. 
  
S.No. Characteristics Results 
1. Physical state 
White to off white  
crystalline powder  
 odourless 
2. Solubility Analysis 
Insoluble (342mg/lit) 
3. Bulk density 1.18 g/cm3 
4. Tap density 0.221g/ml 
5. Compressibility index 41.11% 
6. Residue on ignition 1% max 
7. pH 8-10 
8. Optical rotation 890 -950 
9.. Loss on drying 3% max 
10 Melting point 2200C  
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FIG. 12 : I.R. SPECTRA FOR CLARITHROMYCIN 
 
Fig.13:  I.R SPECTRA OF HPMC K15M 
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Fig.14: I.R. INTERPRETATION OF PHYSICAL MIXTURE 
 
Table No 2:  Characteristic peaks In FTIR spectra of Clarithromycin 
Wave number 
in cm-1 
Functional 
groups 
Pure drug 
Clarithromycin 
Physical 
mixture 
700-900 C-H Bending 891.60 cm-1 890.58 cm-1 
1020-1070 C-O Stretching 1049.30 cm-1 1049.30 cm-1 
1350-1480 -C-H Bending 1373.95 cm-1 1381.16 cm-1 
1640-1690 C=O Stretching 1691.72 cm-1 1694.11 cm-1 
2500-3300 O-H Stretching 2978.17 cm-1 2978.17 cm-1 
 
7.2. STASTANDARD CALIBRATION CURVE: 
Standard calibration curve of Clarithromycin was drawn by plotting 
absorbance V/s concentration. Themax of Clarithromycin in 0.1N HCl was 
determined to be 203 nm as shown in Fig.15. The absorbance values are tabulated in 
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7.3   Formulation of CiarithromycinTablet (in mgs) 
Table No4: formulation of Hydrodynamically Balanced Tablets of 
Clarithromycin (in mgs) 
Ingredients(in mgs) 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
Clarithromycin 
 500 500 500 500 500 500 500 500 500 500
HPMC K 4 M 
 200 - - - 100 100 100 - - - 
HPMC K 10M 
 - 200 - - 100 - - 100 100  
HPMC K 15M 
 - - 200 - - 100 - 100  100
Chitosan 
 - - - 200 - - 100  100 100
Sodium bicarbonate 
 80 80 80 80 80 80 80 80 80 80 
Lactose 
 10 10 10 10 10 10 10 10 10 10 
Mag.stearate 
 10 10 10 10 10 10 10 10 10 10 
 
7.4 EVALUATION OF HYDRODYNAMICALLY BALANCED TABLET 
FORMULATIONS: 
1.  Evaluation of granules: 
a. Angle of Repose (θ):- The values obtained for angle of repose for all 
formulations are tabulated in Table5. The values were found to be in the range from 
24.30' to 29.88'. This indicates good flow property of the powder blend. 
b. Compressibility Index:- Compressibility index value ranges between 
12.30% to 16.34% indicating that the powder blend have the required flow property 
for direct compression. 
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Table No.5: Angle of Repose, Compressibility Index 
Batch Angle of repose Compressibility index 
F1 24.30 o 12.30 
F2 25.41 o 14.58 
F3 26.77 o 15.67 
F4 28.56 o 16.34 
F5 24.72 o 14.12 
F6 25.28 o 14.48 
F7 27.08 o 14.59 
F8 25.63 o 14.74 
F9 28.45 o 15.34 
F10 29.88 o 15.41 
 
2.    Evaluation of tablet: 
a) Shape of the tablet:- 
Microscopic examination of tablets from each formulation batch showed 
circular shape with no cracks. 
b) Tablet dimensions:- 
The dimensions determined for formulated tablets were tabulated in Table6. 
Tablets mean thickness (n=3) were almost uniform in all the five formulations and 
were found to be in the range of 5.12mm to 5.18mm. The diameter of the tablet 
ranges between 12.98mm to 12.99mm. 
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c)Thickness  
The dimensions of the tablet like thickness, length were measured using 
vernier-calipers. Ten tablets were selected randomly for this test and the average 
value was reported. 
d) Hardness test:- 
The measured hardness of tablets of each batch ranged between 4.1 to 
4.5kg/cm2 (Table6). This ensures good handling characteristics of all batches. 
e) Friability Test:- 
The values of friability test were tabulated in Table 6. The % friability was 
less than 1% in all the formulations ensuring that the tablets were mechanically 
stable. 
.f) Weight Variation Test:- 
The percentage weight variation for all formulations were shown in Table 6. 
All the tablets passed weight variation test as the % weight variation was within the 
pharmacopoeial limits of ±5% of the weight. The weight of all the tablets were 
found to be uniform with low standard deviation values. 
g) Drug Content Uniformity:- 
The percentage of drug content was found to be between 97.4% to 99.5% of 
Clarithromycin, which was within acceptable limits. Table 6 showed the results of 
drug content uniformity in each batch 
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Table No.6: Physical Properties of Tablets of Batch F1 to F10 
 
h) Tablet density:- 
To provide good floating behavior in the stomach, the density of the device 
should be less than that of the gastric contents (1.004g/cm3). All the batches showed 
density below than that of gastric fluid (1.004). The values are shown in Table7. 
When tablet contacts the test medium, tablet expanded (because of swellable 
polymers) and there was liberation of CO2 gas (because of effervescent agent, 
NaHCO3). The density decreased due to this expansion and upward force of CO2 gas 
generation. This plays an important role in ensuring the floating capability of the 
dosage form. 
Batch Diameter thickness hardness friability Weight 
variation 
Drug 
content 
F1 12.99 ±0.04 5.16 ±0.01 4.5 ±0.47 0.41 800.65 ±1.29 97.01 
F2 12.98 ±0.01 5.15 ±0.02 4.4 ±0.1 0.40 800.41 ±1.12 98.35 
F3 12.98 ±0.006 5.14 ±0.01 4.4 ±0.32 0.36 800.50 ±1.74 99.50 
F4 12.98 ±0.07 5.16 ±0.01 4.3±0.42 0.38 800.05 ±1.37 97.40 
F5 12.98 ±0.04 5.15 ±0.03 4.2±0.41 0.37 801.10 ±1.13 99.40 
F6 12.99 ±0.067 5.12 ±0.06 4.1±0.54 0.38 799.55 ±1.18 98.01 
F7 12.98 ±0.05 5.16 ±5.15 4.2±0.32 0.42 799.85 ±1.65 99.21 
F8 12.99 ±0.06 5.15 ±0.02 4.3±0.65 0.38 800.03 ±1.11 98.69 
F9 12.98 ±0.02 5.16 ±0.03 4.4±0.41 0.39 800.68 ±1.35 98.98 
F10 12.98 ±0.056 5.18 ±0.01 4.5±0.35 0.37 801.65 ±1.49 98.40 
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i) Buoyancy Study:- 
On immersion in 0.1N HCl solution pH (1.2) at 370C, the tablets floated, and 
remained buoyant without disintegration. Table 7 shows the results of Buoyancy 
study & shows Buoyancy character of prepared tablet. 
From the results it can be concluded that the batch containing only HPMC 
polymers showed good Buoyancy lag time (BLT) and Total floating time (TFT).  
Formulation F3 containing HPMC K15M showed good BLT of 49 sec, while 
the formulation containing chitosan alone and in combination with HPMC K15M 
showed highest BLT, and TFT of less than 12 hrs. This may be due to the amount of 
polymer and gas generating agent, which were kept constant in the present study. 
The gas generated cannot be entrapped inside the gelatinous layer, and it escapes 
leading to variation in BLT and TFT. 
Table no.7: Tablet Density, Buoyancy Lag Time,  TotalFloatingTime   
 
 
 
 
 
 
 
Batch Tablet density Buoyancy lag 
time (sec) 
Total floating 
time(Hrs) 
F1 0.93 62 >12 
F2 0.88 54 >12 
F3 0.82 49 >12 
F4 0.99 134 >6 
F5 0.85 58 >12 
F6 0.89 55 >12 
F7 0.95 125 >7 
F8 0.86 118 >12 
F9 0.93 107 >9 
F10 0.90 102 >10 
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j) Swelling Study:- 
Swelling ratio describes the amount of water that is contained within the 
hydrogel at an equilibrium and is a function of the network structure, hydrophilicity 
and ionization of the functional groups. 
Swelling study was performed on all the batches for 5 hr. The results of 
swelling index is given in Table8. While the plot of swelling index against time (hr) 
is depicted in Fig.16. 
From the results it was concluded that swelling increases as the time passes 
because the polymer gradually absorb water due to hydrophilicity of polymer. The 
outermost hydrophilic polymer hydrates and swells and a gel barrier is formed at the 
outer surface. As the gelatinous layer progressively dissolves and/or is dispersed, the 
hydration swelling release process is repeated towards new exposed surfaces, thus 
maintaining the integrity of the dosage form. 
In the present study, the higher swelling index was found for tablets of batch 
F3 containing HPMC K15M having nominal viscosity of 15,000 cps. Thus, the 
viscosity of the polymer had major influence on swelling process, matrix integrity, 
as well as floating capability, hence from the above results it can be concluded that 
linear relationship exists between swelling process and viscosity of polymer. 
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Table No.8: Swelling Index of Tablets of Batch F1 to F10 
 
Time 
in 
Hrs 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1 30 31 32 29 28 29 27 30 30 31 
2 46 47 48 43 45 44 46 48 47 45 
3 61 63 64 60 60 61 60 62 63 61 
4 80 81 82 75 77 79 77 80 81 82 
5 92 94 95 88 89 90 88 92 93 94 
 
Fig. No. 16: Swelling Index 
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k) Effect of hardness on Buoyancy Lag Time:- 
The effect of hardness on buoyancy lag time for batch F3was studied. The 
results of floating lag time of tablet having hardness of 5kg/cm2, 7kg/cm2 and 
9kg/cm2 were 102, 480 and 650 sec respectively as tabulated in Table 9. The plot of 
floating lag time (sec) V/s hardness (kg/cm2). Batch F3 was selected for the study 
because it showed buoyancy lag time of 49 sec at hardness of 4kg/cm2. 
Buoyancy of the tablet was governed by both the swelling of the 
hydrocolloid particle on surface when it contacts the gastric fluid which in turn 
results in an increase in the bulk volume and the presence of internal void space in 
the dry center of the tablet (porosity). On increasing the hardness of the tablets 
results in increased buoyancy lag time which might be due to high compression 
resulting in reduction of porosity of the tablet and moreover, the compacted  
hydrocolloid particles on the surface of the tablet cannot hydrate rapidly when the 
tablet reaches the gastric fluid and as a result of this, the capability of the tablet to 
float is significantly reduced. 
Table No.9: Effect of Hardness on Buoyancy Lag Time of Batch F3 
Hardness in kg/cm2 Buoyancy Lag Time (sec)
4kg/cm2 49 
5kg/cm2 102 
7kg/cm2 480 
9kg/cm2 650 
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l) In-vitro Dissolution Study:- 
The in-vitro drug release profile of tablet from each batch (F1 to F10) were 
shown in Table10. The plot of % cumulative drug release V/s time (hr) was plotted 
and depicted as shown in Fig.17. 
For in-vitro dissolution study ring mesh device was used. The reason is that 
when paddle apparatus is used, the tablets would rise and eventually stick to the 
flange of the rotating shaft resulting in partial surface occlusion. In case of basket 
apparatus, it ensures full exposure of all surfaces of hydrophilic swelling tablets that 
may stick to bottom of dissolution vessel if paddle apparatus was used. However, it 
was observed that after 5-7 hr the tablets had swollen to such an extent that they 
were completely constricted by the radius of the basket and completely filled the 
bottom of the basket. Once the dosage forms completely fills the basket, tablet is 
unable to swell further and move in unimpeded fashion leading to limited drug 
release. In order to overcome these drawbacks ring mesh device is employed in the 
study. 
From the in-vitro dissolution data it was found that formulation F4 
containing chitosan alone released 97.2% of drug within 6 hr of the study indicating 
that the polymer amount is not sufficient to control the drug release. 
Formulation F3 containing HPMC K15M showed better control of drug 
release than chitosan alone, and released 96.3% drug at the end of 10 hr. Tablet of 
batch F1, F2 and F3 contained same amount of polymer of different grades viz. 
HPMC K4M, HPMC K15M and combination of HPMC K4M and K15M which 
showed drug release rate of 93.6%, 92.1% and 89.3% respectively. Out of all the ten 
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m) Curve Fitting Analysis:- 
The results of dissolution data fitted to various drug release kinetic 
equations. Peppas model was found to be best fitted in all dissolution profile having 
higher correlation coefficient (r value) followed by Higuchi model and Zero Order 
Release equation. The kinetic values obtained for different formulations are 
tabulated in Table11. 
Korsemeyer-Peppas model indicates that release mechanism is not well 
known or more than one type of release phenomena could be involved. The ‘n’ value 
could be used to characterize different release mechanisms as:  
n Mechanism 
0.5 Fickian diffusion (Higuchi Matrix)
0.5 < n < 1 Non-Fickian diffusion 
1 Case II transport 
 
The results are reported in Table 9 and in the present study ‘n’ value ranges 
between 0.64 to 0.76 for all ten batches. It ranges between 0.5 to 1, so it was 
concluded that the drug release occurred via non-Fickian diffusion, which shows 
that the release from initially dry, hydrophilic glassy polymers that swell when 
added to water and become rubbery show anomalous diffusion as a result of the 
rearrangement of macromolecular chains. 
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Table No.11:Kinetic Values Obtained From F3 plot Formulation 
 
7.6 Comparison with Commercial Marketed Product:- 
The promising formulation (F3) as found by evaluation studies was 
compared with marketed product Clarithro ER (500mg). The evaluation parameters 
tested and compared were drug content uniformity and in-vitro dissolution profile. 
The values obtained for in vitro dissolution study are recorded in Table no 8. 
The mean value of drug content uniformity observed was 99.28%. The 
marketed product gave 92.31% of drug release in 10 hrs of dissolution study. In-
vitro dissolution profile of marketed product in comparison to the formulated 
batches were shown graphically in Fig 22 and showed that the formulation F3 with 
89.4% of drug release has better control over release of drug in comparison to 
marketed product. 
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Table no:13 Kinetic studies of optimum formulation F3 
Time 
in 
hours 
√ T Log T 
Cumulative 
% drug 
release 
Cumulative 
% drug 
remain 
Log 
cumulative 
% drug 
release 
Log 
cumulative 
% drug  
remain 
0 0 0 0 100 0 2 
1 1.0 0 20.70 79.3 1.315 1.899 
2 1.414 0.301 31.54 68.46 1.498 1.835 
3 1.732 0.477 46.87 53.13 1.670 1.725 
4 2.0 0.602 53.12 46.88 1.725 1.670 
5 2.236 0.698 62.14 37.86 1.793 1.578 
6 2.449 0.778 68.45 31.55 1.835 1.498 
7 2.645 0.845 73.85 26.15 1.868 1.417 
8 2.828 0.903 78.34 21.66 1.893 1.335 
9 3.0 0.954 84.35 15.65 1.926 1.194 
10 3.162 1.0 89.43 10.57 1.951 1.024 
 
7.7 STABILITY STUDIES OF FLOATING TABLETS OF 
CLARYTHROMYCIN 
Table No:14 CHARACTERISTICS OF OPTIMIZED TABLET 
 
Drug Content (%)  
±SD 
Hardness 
(Kg/cm2) 
± SD 
Floating behaviour 
Floating lag 
time (sec) 
Floating 
duration 
(hrs) 
After one 
month 89.24 ±0.029 4.4 ± 0.32 49 13 
After two 
months 89.04 ±0.024 4.5 ± 0.43 52 13 
After three 
months 88.87 ±0.025 4.56 ± 0.36 58 12 
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Table No.:15  IN-VITRO DRUG RELEASE STUDY  
Time 
(in 
hours) 
Cumulative drug 
release after one 
month 
Cumulative drug 
release after two 
months 
Cumulative drug 
release after 
three months 
0 0.000 0.00 0.00 
1 20.67 20.57 20.07 
2 31.34 31.68 31.64 
3 46.80 47.20 46.60 
4 52.08 53.12 53.01 
5 62.01 62.23 62.07 
6 68.25 69.23 69.68 
7 73.98 74.20 75.03 
8 78.18 79.28 80.20 
9 84.30 84.75 84.93 
10 89.43 89.38 89.33 
 
Fig.23:   In Vitro Drug Release Study 
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The tablets were investigated at 40oC/75%RH For 3 months.From the data, 
The Formulation is found to be stable under the conditions mentioned before since 
there was no significant change in the percentage amount of drug content and drug 
release. Thus, it was found that the Fioating tablets of clarithromycin (F3) were 
stable under these conditions at least for three months. 
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8. SUMMARY AND CONCLUSION 
In the present study Gastroretentive delivery systems of Clarithromycin were 
successfully developed in the form of Hydrodynamically Balanced Tablets to 
improve the local action and ultimately its bioavailability. 
The tablets were formulated using different grades of polymers (HPMC 
K4M, HPMC K15M and Chitosan) and effervescing agent (NaHCO3). 
IR spectra studies revealed that the drug and the polymers used were 
compatible. The evaluation parameters like hardness, friability and content 
uniformity were within the limits for various batches formulated. 
Buoyancy lag time, Total floating time, tablet density, Swelling studies 
showed satisfactory results for batch F1, F2, F3, F5, F6 and F8. The formulation F3 
was evaluated for effect of hardness on floating lag time, and the results showed that 
the floating lag time increased as hardness increased due to reduction in porosity. 
In-vitro dissolution of batch F3 containing  HPMC K15M showed good drug 
release rate in comparison to remaining batches  containing chitosan, HPMC K4M, 
HPMC K10M  which were not able to sustain their release up to 10 hrs. 
Formulations subjected to curve fitting analysis showed to best fit Korsemeyer – 
Peppas equation and followed non-Fickinian diffusion mechanism. 
Comparison study with marketed product Clarithro ER showed that the 
optimized formulation F3 has better control over release rate in comparison with the 
marketed product. 
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Hence it was concluded that formulation F3 containing HPMC K15M 
showed better controlled drug release rate in comparison to other polymers and 
showed that the release decreases as the viscosity of the polymer increases. 
From the findings obtained, it can be concluded that:- 
¾ Hydrodynamically Balanced Tablets of an antibacterial drug Clarithromycin can 
be formulated as an approach to increase gastric residence time and thereby 
improve its bioavailability. 
¾ Among the polymers used to improve the gastric residence, cellulose polymers 
HPMC K4M, HPMC K15M showed better control over drug release in 
comparison to polysaccharide polymer Chitosan. 
¾ Formulated tablets gave satisfactory results for various physicochemical 
evaluation for tablets like Tablet dimensions, Hardness, Friability, Weight 
variation, Tablet density, Swelling index and Content uniformity. 
¾ Overall, tablets of batch F3 possessed quick buoyancy lag time and good total 
floating time. 
¾ Variation on hardness on tablet of batch F3 was found to effect the floating lag 
time of the tablet as hardness increased. 
¾ In-vitro release rate showed that the drug release was better controlled in 
formulation F3 shows better control drug release in comparision to other 
formulation. 
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¾ Formulated floating tablets best fitted to Peppas model followed by Higuchi 
model and Zero order rate kinetics. 
¾ Formulation F3 has better Sustained drug release in comparison to marketed 
product Clarithro ER. 
¾ The present work can be continued further to prove its stability during shelf  life,         
in-vivo gastric residence time by using gamma scintigraphy and establishment of 
in vitro – in vivo correlation. 
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